PURPOSE: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. METHODS: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. RESULTS: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79% of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60% of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. CONCLUSIONS: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.
PURPOSE: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancerpatients, regarding EGFR mutation testing in advanced NSCLCpatients. METHODS: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancerpatients. RESULTS: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancerpatients in Israel. 79% of them use EGFR testing routinely for all advanced NSCLCpatients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60% of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. CONCLUSIONS:EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLCpatients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.
Authors: Jonathan Weiss; Martin L Sos; Danila Seidel; Martin Peifer; Thomas Zander; Johannes M Heuckmann; Roland T Ullrich; Roopika Menon; Sebastian Maier; Alex Soltermann; Holger Moch; Patrick Wagener; Florian Fischer; Stefanie Heynck; Mirjam Koker; Jakob Schöttle; Frauke Leenders; Franziska Gabler; Ines Dabow; Silvia Querings; Lukas C Heukamp; Hyatt Balke-Want; Sascha Ansén; Daniel Rauh; Ingelore Baessmann; Janine Altmüller; Zoe Wainer; Matthew Conron; Gavin Wright; Prudence Russell; Ben Solomon; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Steinar Sollberg; Odd Terje Brustugun; Walburga Engel-Riedel; Corinna Ludwig; Iver Petersen; Jörg Sänger; Joachim Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle Heideman; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; Michael Hallek; Rameen Beroukhim; William Pao; Bert Klebl; Matthias Baumann; Reinhard Buettner; Karen Ernestus; Erich Stoelben; Jürgen Wolf; Peter Nürnberg; Sven Perner; Roman K Thomas Journal: Sci Transl Med Date: 2010-12-15 Impact factor: 17.956
Authors: Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson Journal: Cancer Discov Date: 2011-06 Impact factor: 39.397
Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson Journal: Science Date: 2004-04-29 Impact factor: 47.728
Authors: Nicholas J Wang; Zachary Sanborn; Kelly L Arnett; Laura J Bayston; Wilson Liao; Charlotte M Proby; Irene M Leigh; Eric A Collisson; Patricia B Gordon; Lakshmi Jakkula; Sally Pennypacker; Yong Zou; Mimansa Sharma; Jeffrey P North; Swapna S Vemula; Theodora M Mauro; Isaac M Neuhaus; Philip E Leboit; Joe S Hur; Kyunghee Park; Nam Huh; Pui-Yan Kwok; Sarah T Arron; Pierre P Massion; Allen E Bale; David Haussler; James E Cleaver; Joe W Gray; Paul T Spellman; Andrew P South; Jon C Aster; Stephen C Blacklow; Raymond J Cho Journal: Proc Natl Acad Sci U S A Date: 2011-10-17 Impact factor: 11.205
Authors: Nick Dragojlovic; Kennedy Borle; Nicola Kopac; Ursula Ellis; Patricia Birch; Shelin Adam; Jan M Friedman; Amy Nisselle; Alison M Elliott; Larry D Lynd Journal: Genet Med Date: 2020-06-24 Impact factor: 8.822